Subtype
Vulvar Squamous Intraepithelial Lesion, HPV-Associated
CI-CAN-00007107Explore in graph →
Non-malignant2 active trials
- NCIt
- C128142
Loading cancer entity…
Subtype
CI-CAN-00007107Explore in graph →
Clinical trials
13 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05104099 | Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia(PhotodiVIN) | completed | Phase 2 | 17 | Institut de Cancérologie de LorraineOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT05717621 | Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN)(DelVIN) | completed | Phase 1 | 29 | ViMREX GmbHINDUSTRY | 1 | Feb 11, 2025 |
| clinicaltrials |
| NCT05372016 | Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03180684 | Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) | completed | Phase 2 | 33 | Inovio PharmaceuticalsINDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT04425291 | Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,680 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 25, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jul 24, 2025source: clinicaltrials